Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Kathy Hibbs, Nelson Chan

Premium

Kathy Hibbs is 23andMe's new chief legal and regulatory officer.

Hibbs joins 23andMe from Genomic Health, where she served as senior vice president and general counsel. She has also worked at Monogram Biosciences and Varian Medical Systems, and is actively engaged in a number of industry groups, such as the American Clinical Laboratory Association, the Coalition for 21st Century Medicine, and the Personalized Medicine Coalition.

Hibbs joins 23andMe while the firm is in the midst of regulatory discussions with the US Food and Drug Administration regarding its Personal Genome Service. Last November, 23andMe received a warning letter in which the agency asked the personal genomics company to stop marketing health-related information to customers without its clearance. While the regulatory issues are being ironed out, 23andMe continues to provide new customers their raw, uninterpreted genomic data and ancestry-related reports.


Nelson Chan has been appointed to the board of Jade Sky Technologies, an LED driver manufacturer.

Chain is a director of Affymetrix, Synaptics, and Bridgelux, and is chairman of the board of Outerwall. He is also a former CEO of Magellan.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.